Literature DB >> 27699263

Incomplete clonal deletion as prerequisite for tissue-specific minor antigen tolerization.

Nina Pilat1, Benedikt Mahr1, Lukas Unger1, Karin Hock1, Christoph Schwarz1, Andreas M Farkas1, Ulrike Baranyi1, Fritz Wrba2, Thomas Wekerle1.   

Abstract

Central clonal deletion has been considered the critical factor responsible for the robust state of tolerance achieved by chimerism-based experimental protocols, but split-tolerance models and the clinical experience are calling this assumption into question. Although clone-size reduction through deletion has been shown to be universally required for achieving allotolerance, it remains undetermined whether it is sufficient by itself. Therapeutic Treg treatment induces chimerism and tolerance in a stringent murine BM transplantation model devoid of myelosuppressive recipient treatment. In contrast to irradiation chimeras, chronic rejection (CR) of skin and heart allografts in Treg chimeras was permanently prevented, even in the absence of complete clonal deletion of donor MHC-reactive T cells. We show that minor histocompatibility antigen mismatches account for CR in irradiation chimeras without global T cell depletion. Furthermore, we show that Treg therapy-induced tolerance prevents CR in a linked suppression-like fashion, which is maintained by active regulatory mechanisms involving recruitment of thymus-derived Tregs to the graft. These data suggest that highly efficient intrathymic and peripheral deletion of donor-reactive T cells for specificities expressed on hematopoietic cells preclude the expansion of donor-specific Tregs and, hence, do not allow for spreading of tolerance to minor specificities that are not expressed by donor BM.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27699263      PMCID: PMC5033814          DOI: 10.1172/jci.insight.85911

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  45 in total

1.  Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance.

Authors:  A D Wells; X C Li; Y Li; M C Walsh; X X Zheng; Z Wu; G Nuñez; A Tang; M Sayegh; W W Hancock; T B Strom; L A Turka
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

Review 2.  Mixed chimerism and split tolerance: mechanisms and clinical correlations.

Authors:  David P Al-Adra; Colin C Anderson
Journal:  Chimerism       Date:  2011 Oct-Dec

3.  Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection.

Authors:  Susan Stewart; Gayle L Winters; Michael C Fishbein; Henry D Tazelaar; Jon Kobashigawa; Jacki Abrams; Claus B Andersen; Annalisa Angelini; Gerald J Berry; Margaret M Burke; Anthony J Demetris; Elizabeth Hammond; Silviu Itescu; Charles C Marboe; Bruce McManus; Elaine F Reed; Nancy L Reinsmoen; E Rene Rodriguez; Alan G Rose; Marlene Rose; Nicole Suciu-Focia; Adriana Zeevi; Margaret E Billingham
Journal:  J Heart Lung Transplant       Date:  2005-06-20       Impact factor: 10.247

4.  The Banff 2007 working classification of skin-containing composite tissue allograft pathology.

Authors:  L C Cendales; J Kanitakis; S Schneeberger; C Burns; P Ruiz; L Landin; M Remmelink; C W Hewitt; T Landgren; B Lyons; C B Drachenberg; K Solez; A D Kirk; D E Kleiner; L Racusen
Journal:  Am J Transplant       Date:  2008-07       Impact factor: 8.086

5.  Therapeutic efficacy of polyclonal tregs does not require rapamycin in a low-dose irradiation bone marrow transplantation model.

Authors:  Nina Pilat; Christoph Klaus; Martina Gattringer; Elmar Jaeckel; Fritz Wrba; Dela Golshayan; Ulrike Baranyi; Thomas Wekerle
Journal:  Transplantation       Date:  2011-08-15       Impact factor: 4.939

6.  Long-term prevention of chronic allograft rejection by regulatory T-cell immunotherapy involves host Foxp3-expressing T cells.

Authors:  Lise Pasquet; Jean-Yves Douet; Tim Sparwasser; Paola Romagnoli; Joost P M van Meerwijk
Journal:  Blood       Date:  2013-04-11       Impact factor: 22.113

Review 7.  Clinical trials for induction of renal allograft tolerance.

Authors:  Nahel Elias; A Benedict Cosimi; Tatsuo Kawai
Journal:  Curr Opin Organ Transplant       Date:  2015-08       Impact factor: 2.640

8.  Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells.

Authors:  Angela M Thornton; Patricia E Korty; Dat Q Tran; Elizabeth A Wohlfert; Patrick E Murray; Yasmine Belkaid; Ethan M Shevach
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

9.  Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes.

Authors:  Olivier Joffre; Thibault Santolaria; Denis Calise; Talal Al Saati; Denis Hudrisier; Paola Romagnoli; Joost P M van Meerwijk
Journal:  Nat Med       Date:  2007-12-09       Impact factor: 53.440

10.  Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance.

Authors:  T Wekerle; M H Sayegh; J Hill; Y Zhao; A Chandraker; K G Swenson; G Zhao; M Sykes
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

View more
  8 in total

Review 1.  Murine models of transplantation tolerance through mixed chimerism: advances and roadblocks.

Authors:  B Mahr; T Wekerle
Journal:  Clin Exp Immunol       Date:  2017-05-22       Impact factor: 4.330

2.  Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance.

Authors:  Toshihito Hirai; Teresa L Ramos; Po-Yu Lin; Federico Simonetta; Leon L Su; Lora K Picton; Jeanette Baker; Jian-Xin Lin; Peng Li; Kinya Seo; Juliane K Lohmeyer; Sara Bolivar-Wagers; Melissa Mavers; Warren J Leonard; Bruce R Blazar; K Christopher Garcia; Robert S Negrin
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 19.456

3.  CTLA4Ig Improves Murine iTreg Induction via TGFβ and Suppressor Function In Vitro.

Authors:  Nina Pilat; Benedikt Mahr; Martina Gattringer; Ulrike Baranyi; Thomas Wekerle
Journal:  J Immunol Res       Date:  2018-07-02       Impact factor: 4.818

4.  A Prospective Controlled Trial to Evaluate Safety and Efficacy of in vitro Expanded Recipient Regulatory T Cell Therapy and Tocilizumab Together With Donor Bone Marrow Infusion in HLA-Mismatched Living Donor Kidney Transplant Recipients (Trex001).

Authors:  Rainer Oberbauer; Matthias Edinger; Gabriela Berlakovich; Peter Kalhs; Nina Worel; Georg Heinze; Michael Wolzt; Thomas Lion; Thomas Wekerle
Journal:  Front Med (Lausanne)       Date:  2021-01-27

5.  Distinct roles for major and minor antigen barriers in chimerism-based tolerance under irradiation-free conditions.

Authors:  Benedikt Mahr; Nina Pilat; Nicolas Granofszky; Moritz Muckenhuber; Lukas W Unger; Anna M Weijler; Mario Wiletel; Romy Steiner; Lisa Dorner; Heinz Regele; Thomas Wekerle
Journal:  Am J Transplant       Date:  2020-07-24       Impact factor: 8.086

6.  Treg Therapies Revisited: Tolerance Beyond Deletion.

Authors:  Nina Pilat; Jonathan Sprent
Journal:  Front Immunol       Date:  2021-01-28       Impact factor: 7.561

7.  Anti-Interleukin-6 Promotes Allogeneic Bone Marrow Engraftment and Prolonged Graft Survival in an Irradiation-Free Murine Transplant Model.

Authors:  Nicolas Granofszky; Andreas M Farkas; Moritz Muckenhuber; Benedikt Mahr; Lukas Unger; Svenja Maschke; Nina Pilat; Raimund Holly; Mario Wiletel; Heinz Regele; Thomas Wekerle
Journal:  Front Immunol       Date:  2017-07-19       Impact factor: 7.561

Review 8.  Combining Adoptive Treg Transfer with Bone Marrow Transplantation for Transplantation Tolerance.

Authors:  Nina Pilat; Nicolas Granofszky; Thomas Wekerle
Journal:  Curr Transplant Rep       Date:  2017-11-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.